Pharmacokinetics of meropenem in patients with cystic fibrosis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 12, 1998, Pages 873-876

  Christensson, B A ^b   Ljungberg, B ^a   Eriksson, L ^a   Nilsson Ehle, I ^a  

^a LUND UNIVERSITY   (Sweden)

^b Visby Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MEROPENEM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; PLASMA CLEARANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0032422081     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050211     Document Type: Article

References (15)

1. 1. Bauernfeind A, Jungwirth R, Schweighart: In vitro activity of meropenem, imipenem, the penem HRE 664 and ceftazidime against clinical isolates from West Germany. Journal of Antimicrobial Chemotherapy (1989) 24, Supplement A: 73-84
2. 2. King A, Boothman C, Phillips I: Comparative in vitro activity of meropenem on clinical isolates from the United Kingdom. Journal of Antimicrobial Chemotherapy (1989) 24, Supplement A: 31-45
3. 3. Webb AK: The treatment of pulmonary infection in cystic fibrosis. Scandinavian Journal of Infectious Diseases (1995) 96, Supplement: 24-27
4. 4. Christensson BA, Nilsson-Ehle I, Ljungberg B, Lindblad A, Malmborg A-S, Hjelte L, Strandvik B: Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy (1992) 36:2512-2517
5. 5. Jusko WJ, Mosovich LL, Gerbracht M, Matter ME, Yaffe SJ: Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics (1975) 56:1038-1044
6. 6. Spino M: Pharmacokinetics of drugs in cystic fibrosis. Clinical Reviews in Allergy (1991) 9:169-210
7. 7. Krutzén E, Bäck SE, Nilsson-Ehle I, Nilsson-Ehle P: Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. Journal of Laboratory and Clinical Medicine (1984) 104:955-961
8. 8. Burman LÅ, Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby RN: Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. Journal of Antimicrobial Chemotherapy (1991) 27:219-224
9. 9. Bentur U, Spino M, Gold R, Tesoro M, Martin S, Pop RD, Levy M, Heurter H: Enhanced ciprofloxacin clearance in cystic fibrosis (CF) patients. Clinical Pharmacology and Therapeutics (1990) 47:185
10. 10. Reed MD, Stern RC, O'Brien A, Yamashita TS, Myers CM, Blumer JL: Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy (1985) 22:583-588
11. 11. Strandvik B, Malmborg A-S, Bergan T, Michalsen H, Storrösten OT, Wretlind B: Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy (1988) 21:471-480
12. 12. Steffens T, Holohan P, Ross C: Operational modes of the organic anion exchange in canine renal brush-border membrane vesicles. American Journal of Physiology (1989) 256:F596-F609
13. 13. Katz SM, Krueger LJ, Falkner B: Microscopic nephrocalcinosis in cystic fibrosis. New England Journal of Medicine (1988) 319:263-266
14. 14. Strandvik B, Berg U, Kallner A, Kusoffsky E: Effect on renal function of essential fatty acid supplementation in cystic fibrosis. Journal of Pediatrics (1989) 115:242-250
15. 15. Schentag JJ: Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scandinavian Journal of Infectious Diseases (1991) 74, Supplement: 218-234